You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Les traitements par chimiothérapie et autres traitements systémiques pourraient être modifiés en raison de la COVID-19. Vous trouverez de plus amples renseignements à la page Traitements systémiques pendant la pandémie de la COVID-19.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Formulaire de médicaments
À propos du Formulaire de médicaments Courriel de l’équipe du Formulaire de médicaments

Médicaments

La bibliothèque de médicaments donne accès à des renseignements sur plus de 100 médicaments anticancéreux commercialisés au Canada.

Trouvez plus d’information sur la sécurité dans les documents patient supplémentaire:

Comment prendre vos médicaments oraux contre le cancer de manière sécuritaire

Manipulation sécuritaire des médicaments contre le cancer et des fluides corporels à la maison

Displaying Drugs List

173 articles
Other Name(s): Verzenio™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jul 2020
Other Name(s): Zytiga® (Janssen)
Funding:
Exceptional Access Program
  • abiraterone - Metastatic castrate-resistant prostate cancer, with specific criteria
... Show more tags
Quick Link(s):
Drug Monograph, Patient Info Sheet
Sep 2019
Other Name(s): Calquence®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jan 2021
Other Name(s): Giotrif®
Funding:
Exceptional Access Program
  • AFAtinib - For first-line monotherapy treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC), according to specific criteria
... Show more tags
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jun 2019
Other Name(s): Proleukin® (interleukin-2)
Funding:
New Drug Funding Program
  • Aldesleukin (interleukin-2) - In-Transit Metastases from Melanoma
... Show more tags
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jun 2019
Other Name(s): Alecensaro™
Funding:
Exceptional Access Program
  • Treatment of non-small cell lung cancer according to clinical criteria
... Show more tags
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jun 2019
Other Name(s): MabCampath®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Sep 2019
Other Name(s): AMSA P D® (Erfa)
Quick Link(s):
Drug Monograph
Sep 2011
Other Name(s): Agrylin® (Shire Pharma)
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jul 2017
Other Name(s): Arimidex®
Funding:
ODB - General Benefit
  • anastrozole
... Show more tags
Quick Link(s):
Drug Monograph, Patient Info Sheet
Updated
Mar 2021
Other Name(s): Erleada®
Funding:
Exceptional Access Program
  • apalutamide - For the treatment of non-metastatic castration resistant prostate cancer (nmCRPC) according to clinical criteria
... Show more tags
Quick Link(s):
Drug Monograph, Patient Info Sheet
Feb 2021
Other Name(s): Trisenox®
Funding:
New Drug Funding Program
  • Arsenic Trioxide - First Line Consolidation of Acute Promyelocytic Leukemia (APL)
  • Arsenic Trioxide - First Line Induction of Acute Promyelocytic Leukemia (APL)
  • Arsenic Trioxide - Relapsed_Refractory Induction of Acute Promyelocytic Leukemia (APL)
  • Arsenic Trioxide - Relapsed_Refractory Consolidation of Acute Promyelocytic Leukemia (APL)
... Show more tags
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jan 2021